Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Original abstract agrees with338randomized adults,24-week primary and48-week secondary weights and high-dose5%responders. This supports trial efficacy, not a modern active-comparator superiority claim. Fulltrial Methods/supplementwere not fully audited. Original PMID37366315. Access: abstract_metadata.
Original abstract confirms537participants and treatment-regimen weight change−11.5%to−15.3%versus−2.6%placebo. Primary endpointisHbA1c and entryBMI≥23; whole-cohort weights do not exactly estimate the preregistered obesity/overweight subset. Original PMID42250575. Access: abstract_metadata.
Original PMID42814954 confirms peer-reviewed29September2026results,2339randomizedparticipants and80-week treatment-regimen weights up to−25.0%versus−3.9%placebo. Provider corpus omission is not absenceofpublication.80weeks is longer-horizon corroboration beyond our registered24–72weeks. IndexedOSA sign inconsistency is flagged without repeatingthatnumber. Original PMID42814954. Access: abstract_metadata.
Original PMID42810372 confirms1152randomized adults withBMI≥27andT2D, multiple-imputation treatment-regimen weight results at80weeks and tolerability signals. This resultisavailablebeforecutoff; provider gap cannotbe called a researchgap. Original PMID42810372. Access: abstract_metadata.
Original randomized double-dummy phase2 report confirms36-week retatrutideweight loss beyond dulaglutide1.5mg atdoses≥4mg, but cannot establish superiorityoverobesity-dose semaglutide/tirzepatide. Original PMID37385280. Access: abstract_metadata.
Selected original Methods/Results retain self-reportedhigher-dose hunger effects, but satiety/fullness and aggregate appetite-to-weight correlations are oftennull. These are samephase2participants, not a newtrial or proof of receptor-specific mediation. Original PMID40916752. Access: full_text_partial.
Selected originalbodyconfirms post-hoc phase2analyses and exclusionofpost-discontinuation/rescue samples. Inflammationcontrasts are nonsignificant inT2D but somepositive in non-diabetes. Surrogates are not hardcardiovascularoutcomes or independentclinicalcausallines. Original PMID42608321. Access: full_text_partial.
Our original class-product testing issemaglutide, notretatrutide, andhighest-risk vendor sampling islimited. Results report upper-bound endotoxinvalues fortwo samples and anelevatedmeasuredvalueforone despiteabstractbroadwording. Suchdataestablishesfailuremodes, not everyretatrutidevialquality. Original PMID39509151. Access: full_text_partial.
Original2025retatrutideDXAsubstudyexists andshows higher-dosefat-massreduction, but only103completed bothscans. Leanmassproportions do notprove musclefunction or absenceofsarcopenia; thissamephase2trialdoesnotcreateanindependence line. Original PMID40609566. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.